You seem to be accessing the site outside of your preferred location. To to make this your preferred location, check the box below.

Company History

3:06

40 Years of St. Jude Medical

Ever since a patient received our revolutionary first heart valve, a product that changed the industry and quickly became the gold standard, we have transformed patients’ lives.

St. Jude Medical 40th Anniversary Fact Sheet

40th Anniversary Fact: Approximately 70 million patients have been touched by our lifesaving technologies. Learn more about our 40-year legacy of notable firsts and innovation.

Engineer examining a medical device in a research and development lab
Challenge Everything

We are committed to building meaningful health care solutions. That means we challenge the status quo.

 

Our History: Investing in People and Ideas

We are inventors, driven by a passion for saving and improving lives through medical technology. Ever since a patient received our revolutionary first heart valve, a product that changed the industry and quickly became the gold standard, we have challenged the status quo. Through internal breakthroughs and strategic acquisitions, we build our product portfolios to transform disease management and meet our customers’ needs.

But our history is not just about our innovations and acquisitions. It is also about our people:

  • The engineers and designers committed to rigorous research to improve medical devices and create new solutions
  • The sales teams, who communicate with our customers to learn what tools and approaches they need to more effectively manage diseases
  • The physicians, who partner with us to pioneer new technologies and better their patients’ lives
  • The leaders, who are nimble and forward-thinking while drawing on their varied experiences, and who believe that every person, idea and dollar is important

Today we are a global corporation with 18,000 employees in 40 countries, with that same entrepreneurial spirit inspiring all we do. With our 40-year history of transforming patients’ lives, we are positioned more than ever as a leader dedicated to treating expensive epidemic diseases.

 
1996
 

Acquired

Daig Corp.

Biocor

Telectronics Pacing Systems


Cardiac catheters enter our product lineup.

2001
 

Our Integrity™ AFx pacemaker is the first FDA-approved device to offer clinically proven stimulation therapy to suppress atrial fibrillation.

2005
 

Acquired

Savacor

Endocardial Solutions (ESI)

Advanced Neuromodulation Solutions

2008
 

Acquired

Radi Medical Systems

MediGuide

EP Medsystems


Unify Quadra™ CRT-D, the industry’s first quadripolar pacing system in a small footprint, receives CE Mark approval.

2010
 

Acquired

LightLab Imaging

AGA Medical

2012
 

Our MediGuide™ Technology launches, becoming the first 3-D navigational system to pinpoint device location on pre-recorded X-ray images, reducing exposure to X-rays during procedures and implants.

2014
 

Acquired

CardioMEMS

NeuroTherm


Prodigy™ SCS System with Burst Technology*, the first and only implantable neuromodulation system that delivers Burst stimulation, receives CE Mark approval.

The world’s first and only upgradeable neurostimulator receives FDA approval as we introduce Protégé™ Neurostimulation System for chronic pain.

CardioMEMS™ HF System gets FDA approval. The device monitors pulmonary artery (PA) pressure to enable early intervention for heart failure.

TactiCath™ Quartz Ablation Catheter earns FDA approval, providing physicians with measurements of the contact force applied by the catheter tip to the heart wall during ablation procedures.

Our Optis™ Integrated System, combining OCT imaging with angiography, secures both CE Mark and FDA clearance

2016
 

Celebrating our 40-year history of transforming patients’ lives.

40 years of transforming patients' lives

St. Jude Medical™ Axium™ Neurostimulator System for dorsal root ganglion (DRG) stimulation received FDA approval.

The industry’s first MultiPoint™ Pacing technology receives FDA approval as we introduce Quadra Assura MP™ CRT-D, Quadra Allure MP™ CRT-P and two new quadripolar Quartet™ LV leads.


We launch the Trifecta™ Valve with Glide™ Technology globally.

1958
 

A Patient in Sweden receives the first fully implantable pacemaker (via Pacesetter/Siemens acquisition).

1990
 

Operations go global as our International Division begins in Brussels, Belgium.

1994
 

Acquired

Pacesetter


Our portfolio expands to include cardiac rhythm management (CRM).

1997
 

Acquired

Ventritex

1999
 

Acquired

Angio-Seal™ Technology

2003
 

Acquired

Getz Bros. Ltd.

2004
 

Acquired

Irvine Biomedical

Epicor Medical

2006
 

Our Merlin™ Patient Care System gets FDA approval; this portable system is designed with flexibility and efficiency in mind.


Optim™ Lead Insulation, the first hybrid lead insulation material specifically designed for leads used with pacemakers and implantable cardioverter defibrillators (ICDs), launches in the U.S.

2009
 

Our Penta™ Lead Is FDA Approved, introducing the first five-column neurostimulation lead to manage chronic pain.

2011
 

Our ILUMIEN™ PCI Optimization System Launches. It is the first to combine fractional flow reserve (FFR) and optical coherence tomography (OCT) technologies.

2013
 

Acquired

Endosense

Nanostim


Nanostim™ Leadless Pacemaker, the first of its kind, receives CE Mark approval in Europe.*

2015
 

Acquired

Spinal Modulation, Inc.

Thoratec Corporation


The FlexAbility™ Ablation Catheter receives FDA approval It is the first and only irrigated ablation catheter with a flexible tip.

The St. Jude Medical™ Invisible Trial System receives CE Mark and FDA approval. It is the industry’s first spinal cord stimulation trial system to incorporate Bluetooth™ wireless technology and Apple™ digital devices.

The 27 mm and 29 mm Portico™ Transcatheter Valve Replacement System* receive CE Mark.

The St. Jude Medical Infinity™ Deep Brain Stimulation System** and directional DBS lead receive CE mark.

The HeartMate 3™ Left Ventricular Assist System* earns CE mark, offering physicians in Europe the most advanced ventricular assist technology to support the management of patients with advanced heart failure.

*This therapy is not approved by the FDA for use in the United States. Limited by federal (or U. S.) law to investigational use. Commercially available for use in select international markets.

**PMA pending FDA approval.